Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9
Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.
Read original at benzingaStocks · News reference
Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 12:58 PM
- Checked
- Aug 13, 2026, 12:58 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Ovid Therapeutics Promotes Charles Carter As CFO Succeeding Jeffrey Rona
Read original at benzinga8-K filing — Ovid Therapeutics Inc. (OVID)
Filed: 2026-07-08 AccNo: 0001628280-26-047584 Size: 149 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgar